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Abstract
BACKGROUND: A surrogate marker is a variable commonly used in clinical trials to guide treatment
decisions when the outcome of ultimate interest is not available. A good surrogate marker is one where the
treatment effect on the surrogate is a strong predictor of the effect of treatment on the outcome. We review the
situation when there is one treatment delivered at baseline, one surrogate measured at one later time point,
and one ultimate outcome of interest and discuss new issues arising when variables are time-varying.
METHODS: Most of the literature on surrogate markers has only considered simple settings with one
treatment, one surrogate, and one outcome of interest at a fixed time point. However, more complicated time-
varying settings are common in practice. In this article, we describe the unique challenges in two settings,
time-varying treatments and time-varying surrogates, while relating the ideas back to the causal-effects and
causal-association paradigms.
CONCLUSION: In addition to discussing and extending popular notions of surrogacy to time-varying
settings, we give examples illustrating that one can be misled by not taking into account time-varying
information about the surrogate or treatment. We hope this article has provided some motivation for future
work on estimation and inference in such settings.
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Abstract
Background—A surrogate marker is a variable commonly used in clinical trials to guide 
treatment decisions when the outcome of ultimate interest is not available. A good surrogate 
marker is one where the treatment effect on the surrogate is a strong predictor of the effect of 
treatment on the outcome. We review the situation when there is one treatment delivered at 
baseline, one surrogate measured at one later time point and one ultimate outcome of interest, and 
discuss new issues arising when variables are time-varying.
Methods—Most of the literature on surrogate markers has only considered simple settings with 
one treatment, one surrogate, and one outcome of interest at a fixed time point. However, more 
complicated time-varying settings are common in practice. In this paper, we describe the unique 
challenges in two settings, time-varying treatments and time-varying surrogates, while relating the 
ideas back to the causal-effects and causal-association paradigms.
Conclusions—In addition to discussing and extending popular notions of surrogacy to time-
varying settings, we give examples illustrating that one can be misled by not taking into account 
time-varying information about the surrogate or treatment. We hope this paper has provided some 
motivation for future work on estimation and inference in such settings.
Keywords
Causal inference; observational studies; randomization; surrogacy; time-varying
Introduction: surrogate markers
A surrogate marker is a variable used to guide treatment decisions when the outcome of 
ultimate interest is not available. In clinical trials, commonly used surrogate markers include 
laboratory values, body weight, and blood pressure. What makes a good surrogate marker is 
different than what makes a good biomarker. A good biomarker is a variable that is a strong 
predictor of the outcome of interest. A good surrogate marker is one where the treatment 
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effect on the surrogate is a strong predictor of the effect of treatment on the outcome. It is 
possible that a variable is a good biomarker, but a poor surrogate marker.
There is a large literature on surrogate markers.1–6 Most of this literature focuses on a 
surrogate marker measured at one time point and an ultimate outcome of interest measured 
at one (typically later) time point. More complicated settings with time-varying variables are 
common in clinical trials; the time varying variables could be treatments, clinical outcomes, 
or surrogate markers. For motivation, consider studies of an antiretroviral drug (ART), 
Zidovudine, to reduce mortality for patients with HIV. A patient’s CD4 count is a known 
surrogate marker for mortality.7 In time-varying settings, another treatment option such as 
Lamivudine can be added during the course of treatments (multiple treatments), or a 
repeated measurement of CD4 count can be treated as another surrogate marker (multiple 
surrogates). The goal of this paper is to discuss new issues that arise when thinking about 
surrogate markers in the context of time-varying variables.
We first review the situation when there is one treatment, one surrogate and one ultimate 
outcome of interest in the Review Section. Then, we discuss new issues arising when there 
are time-varying situations.
Review: one treatment, one surrogate, and one outcome of interest
We review surrogate markers in simple settings, following the arguments of Joffe and 
Greene.8 A surrogate is a variable for which knowing the effect of treatment on the 
surrogate allows prediction of the effect of treatment on the outcome. There are two major 
frameworks for evaluating surrogates: (1) the causal-effects paradigm, and (2) the causal-
association paradigm.
First, to talk about causal inference we need to introduce notation. In what follows, we use 
both potential outcomes or counterfactual language9,10 and graphical models language.11 
Let A denote the (randomized) treatment, S the surrogate, and Y the ultimate outcome of 
interest. Define U as a common cause of S and Y, possibly unmeasured. Let Ya and Sa be the 
outcome and surrogate, respectively, that would be seen under treatment level of a. Causal 
effects are contrasts of potential outcomes for different treatment levels for the same 
subjects. For example, for a binary treatment, a = 0, 1, the effect of treatment for a particular 
subject would be Y1 – Y0, the difference between the outcome a subject would get had 
he/she received the treatment versus what the subject would get had he/she received the 
control. Similarly we also let Ya,s denote the potential outcome that would have been 
observed under treatment level a and surrogate level s. Thus the potential outcome Ya under 
treatment level a can also be expressed as Ya,Sa.
In the causal-effects paradigm, the quality of a surrogate is typically assessed with 
“proportion explained” or “proportion mediated” measures, i.e., how much of the effect of 
treatment is explained or mediated by the surrogate. Thus a variable is considered a good 
surrogate if knowing the causal effect of a treatment on the surrogate along with the causal 
effect of the surrogate on the outcome allows good prediction of the causal effect of the 
treatment on the outcome. We may learn about the effect of the surrogate on the outcome 
from prior experiments or external information, and conduct a surrogate experiment to 
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obtain the effect of a new treatment on the surrogate, from which we would make a decision 
about the effect of new treatment on the outcome.
Freedman et al.12 proposed to measure the proportion of effect explained using the 
framework proposed by Prentice,13 who defined a surrogate as a variable S for which a test 
of the null hypothesis of no relationship to treatment A is also a valid test of no relationship 
to the outcome Y. Operationally, Prentice suggested the following criterion: S is a surrogate 
if it is correlated with the outcome Y and if, once conditioned upon, it renders the treatment 
A and outcome Y independent. The proportion explained approach for a general endpoint 
outcome works as follows. Consider two generalized linear models: one that models Y given 
A directly, g{E(Y | A)} = β0 + AβA, and another that models Y given A and S without 
interaction between A and S, g{E(Y | A, S)} = γ0 + AγA + SγS. Then we can express a 
proportion of the total effect of A explained by S by 1 – γA/βA.12 Freedman et al. consider S 
to be a surrogate if the proportion of effect explained is greater than zero. Although this 
“proportion explained” approach does not utilize explicitly causal ideas, it does seem to 
implicitly require no unmeasured confounding of the effect of S on Y (Figure 1a), which 
unfortunately cannot be ensured by randomization of treatment A.
An alternative approach in the causal-effects paradigm is based on more explicitly causal 
ideas from the mediation literature. The total effect of treatment on the outcome can be 
pieced together from its direct effect and its indirect effect through the surrogate, which we 
now define. Informally, Figure 1b shows the graphical presentation for direct and indirect 
effects. The formal definition involves potential outcome Ya,Sa, which is the outcome that 
would be observed at treatment level a and surrogate Sa. The total effect of treatment, 
Ya=1,S1 – Ya=0,S0, can be decomposed as the sum of a natural direct and indirect effect. The 
subject-level natural direct effect (NDE) of treatment when the surrogate is fixed at its level 
under treatment level a=0 is Ya=1,S0 – Ya=0,S0, a contrast that holds the surrogate constant at 
the value it would have obtained had treatment been set to zero while changing the treatment 
from 1 to 0, and the natural indirect effect (NIE) through the surrogate when treatment is 
fixed at level a=1 is Ya=1,S1 – Ya=1,S0, a contrast holding the treatment constant and 
changing the surrogate from the value it would have obtained under treatment versus 
control;14 the sum of this natural direct effect and natural indirect effect is the total effect of 
treatment, Ya=1,S1 – Ya=0,S0. Another decomposition of the total effect is the natural direct 
effect when the surrogate is fixed at its level under treatment level a=1, Ya=1,S1 – Ya=0,S0, 
plus the natural indirect effect when the treatment is fixed at level a=0, Ya=0,S1 – Ya=0,S0. 
The average direct and indirect effects can be estimated using, for example, a structural 
model approach under the assumption that the initial treatment is randomized or ignorable 
conditional on baseline covariates, and that the surrogate is sequentially ignorable given the 
initial treatment and baseline covariates.8,15
The causal-effects paradigm typically assumes that the surrogate is on the causal pathway 
from the treatment to the outcome. Understanding the way in which the surrogate fits into 
the causal process may be helpful for generalizing whether a variable that is a good 
surrogate in one setting will be a good surrogate in another. However, a drawback of the 
causal effects paradigm is that many surrogates are not causal intermediates (i.e., not on the 
causal pathway), but instead are proxies for causal intermediates. Figure 1c depicts a setting 
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where S* is the causal intermediate but the proxy S is observed; we call such an S a proxy 
surrogate. An example of a proxy surrogate is hemoglobin A1C in diabetes; hemoglobin 
A1C is a proxy for blood sugar and not a causal intermediate -- if there were a way to 
change the amount of glycosylated hemoglobin (what hemoglobin A1C measures) without 
changing levels of blood sugar, it would have little or no effect on health outcomes for 
diabetic patients.
In the causal-association paradigm, evaluation of a surrogate is based on examination of the 
association, across studies or population subgroups, between the effect of a treatment on the 
surrogate and the effect of a treatment on the clinical outcome. A good surrogate is a 
variable for which the effect of a treatment on the surrogate is highly associated with the 
effect of the treatment on the outcome. One approach in this paradigm is based on meta-
analysis.2 The meta-analytic approach examines the relationship across studies between the 
effect of the randomized treatment on the surrogate and the effect of the randomized 
treatment on the clinical outcome. Denote the effect of treatment on surrogate in study j as θj 
and the effect of treatment on outcome in that study as φj. Ideally, for a good surrogate, we 
would find (1) there is a monotonic relationship between θj and φj; (2) when θj is 0, φj is 
also 0; and (3) θj should predict φj well; i.e., in a regression of φj on θj, there should be little 
variability around the regression line. This approach can be applied not only across studies 
but also across specific subgroups defined by baseline covariates within a study. An 
alternative approach in the causal-association paradigm is principal stratification.16 In 
principal stratification, we focus on the association of individual-level effects of A on S and 
on Y; i.e., the association of S1 – S0 with Y1 – Y0. A variable S is called a principal surrogate 
if the effect of treatment on the outcome is 0 in any individual for whom A does not affect 
S.16 Because S1 and S0 are not simultaneously observable in any individual, the causal effect 
of treatment on the surrogate is not observable without further assumptions and so 
assessment of whether S is a principal surrogate requires further assumptions. An advantage 
of the causal-association paradigm is that it deals naturally with proxy surrogates as well as 
causal surrogates. In general, the causal-effects and causal-association paradigms and their 
corresponding approaches can have different advantages in different settings. Which 
approach is used should depend on the specific study goals and on the nature of the putative 
surrogate.6
Time-varying settings
To this point, nearly all of the literature on surrogate markers has considered relatively 
simple settings where the treatment, surrogate, and outcome are all scalars measured at one 
fixed time each. However, more complicated time-varying scenarios are common in 
practice; in fact, Prentice actually considered an example where the surrogate was measured 
over time and the outcome was time-to-event.13 A few authors have considered surrogates 
for failure time outcomes (e.g., Qin et al.17 and Gabriel and Gilbert),18 but to the best of our 
knowledge no one has addressed the problem of evaluating surrogate markers in settings 
where the treatment or surrogate are measured repeatedly over time. We describe the unique 
challenges in these two settings, while relating the ideas back to the two paradigms 
discussed above.
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Time-varying treatments
Before proceeding to time-varying treatments in both causal-effects and causal-association 
paradigms in next paragraphs, we first introduce notation and the concept of global and local 
contrasts for time-varying treatments. We consider two sequential treatments, A1 and A2 
with one surrogate marker S and one clinical outcome Y (Figure 2). In the HIV example, 
treatments A1 and A2 could be Zidovudine and Lamivudine, surrogate S could be patient’s 
CD4 count and clinical outcome Y could be time to death. The effect of treatments on the 
outcome is contrasted under different treatment plans or regimes; e.g.,  and 
. There are global contrasts and local contrasts. Whether S is a good surrogate may 
depend on whether we are interested in global vs. local contrasts. A global contrast 
considers  where ; i.e., we make contrasts over all different 
treatment plans. On the other hand, a local contrast considers different treatments varying at 
only one time point in time; e.g.,  and  for the effect of a blip of treatment at 
time 1 or  and  for the effect of blip of treatment at time 2. The effect of a blip 
of treatment at time j is the causal effect of treatment vs. control at time j conditional on the 
observed past and setting all future treatment to be the control. For statistical inference, we 
could consider marginal structural models for global contrasts and structural nested models 
for local contrasts.19
In the causal-effects paradigm, we typically try to assess how much of the effect of 
treatment on the outcome is explained or mediated by the surrogate. For the proportion 
explained approach in the time-varying setting, we can update the two generalized linear 
models in the Review Section as g{E(Y|A1, A2)} = β0 + A1βA1 + A2βA2 + A1A2βA1A2 and 
g{E(Y|A1, A2, S)} = γ0 + A1γA1 + A2γA2 + A1A2γA1A2 + Sγs. Then, we can express a 
proportion of the total effect of A1 and A2 explained by S as 
.
From the mediation perspective we can discuss effects in terms of global and local contrasts. 
For a global contrast, the overall effect of treatment would be a contrast of what would have 
happened if varying A1 and A2, that is , where 
 and , (all pathways from A1 and A2 to Y in Figure 2a), and the indirect effect 
of treatment involves all pathways except those from treatment directly into the outcome, 
that is, , (A1→Y and A2→Y in Figure 2b).
Note that a variable may be a good surrogate for the joint effect of a time-varying treatment, 
but not for the effect of one treatment alone. This can be assessed using measures of the 
“proportion mediated”, which for the joint effect of A1 and A2 could be expressed as the 
ratio , and similarly for the effect of A1 could be 
expressed as . Given assumptions of consistency and 
randomization of the treatments and surrogate, these measures of proportion mediated can 
be expressed in terms of the observed data as follows:
Hsu et al. Page 5
Clin Trials. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and
For example, consider the simple setting where all variables are binary and both treatments 
A1 and A2 are randomized and the surrogate S is sequentially ignorable, i.e., independent of 
future potential outcomes given A1 and A2, so that the triple (A1, A2, S) is independent of 
potential outcomes Ya1,a2,s and (A1, A2) is independent of potential outcomes Sa1,a2 (and 
similarly for A1 alone). Then, for the data-generating process given in Table 1 (and 
considering the two global contrasts (a1 = 1, a2 = 1) versus (a1 = 0, a2 = 0) and a1 = 1 
versus a1 = 0), S is a good surrogate for A1 and A2 jointly, but not for A1 alone. Specifically, 
one can calculate that the proportion mediated for the joint effect of A1 and A2 is 100%, 
indicating that all of this joint effect is mediated by S, but that the proportion mediated for 
A1 alone is only 3%, indicating that relatively little of the marginal effect of A1 is mediated 
by S. This is the case even though in this example the putative surrogate S is a “consistent 
surrogate” in the sense that the effects of A1 and A2 jointly and of A1 alone (marginally) on 
the surrogate are in the same direction as the corresponding effects on the outcome.6 This 
example illustrates that one can severely underestimate the quality of a surrogate by using 
only partial information about a time-varying treatment.
Focusing on global contrasts may be reasonable if there is a common mechanism for the 
effect of sequential treatments or if the sequential treatments at different times have the 
same contents. For example, the global contrast would make sense in randomized trials with 
time-varying adherence or in observational studies of repeated treatments. It would make 
less sense if the sequential treatments have very different contents such as in sequential, 
multiple assignment, randomized trials (SMARTs).20 For a local contrast, the overall effect 
of treatment A1, , consists of two pathways, one 
that goes through S and one that does not go through S (Figure 3a), and the indirect effect of 
treatment A1 is the pathway that goes through S, that is, , (Figure 
3b).
While we focus on the treatment effect for A1 in the local contrast, we also have to control 
for A2, e.g., A2 = a2. There are multiple possibilities to be considered. For instance, if we are 
investigating an optimal treatment regime, we may want to choose A2 to maximize the 
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utility function or to optimize the outcome. This is not an easy task when a surrogate S is 
still unproven. We may also be interested in the effects of treatment A2. Similarly, there are 
the overall effect of treatment A2, , and the 
indirect effect of treatment A2 with multiple possibilities of treatment A1, 
; see Figure 3c and 3d. In general, a good surrogate for treatment 
A1 or A2 would be, in the causal-effects paradigm, when the indirect effect is close to the 
overall effect and where a positive effect on the surrogate implies a positive effect on the 
outcome. A good surrogate for A1 is not necessary a good surrogate for A2.
In the causal-association paradigm for a time-varying treatment, we focus on the blip of 
treatment for a particular time. For example, let θjt be the effect in study/group j of blip of 
treatment at t on S and let φjt be the effect in group/study j of blip of treatment at t on Y. The 
focus would be on the association between θjt and φjt in this paradigm. Similar to the case of 
scalar quantities, S would be a good surrogate for At, if there is strong association between 
θjt and φjt; and positive effect of At on S implies positive effect on Y. Note that S may be a 
good surrogate for A1, not for A2; or vice versa. Similarly as in the causal effects paradigm, 
we can also consider θjt and φjt for global and local contrasts.
Another example of time-varying treatments can be found in SMARTs. In SMARTs, the 
goal is to find an optimal dynamic treatment regime. Let H1, ...,HT denote the information 
on a subject’s history up to times 1, ..., T; Ht can include the subject’s treatment history 
before time (A1,..., At–1), baseline covariates and intermediate variables that are measured 
after baseline but before or at time t. A dynamic treatment regime is a set of rules π1 (H1),..., 
πT(HT) for assigning treatment at times 1, ..., T based on a patient’s history. The Y-optimal 
dynamic treatment regime is the dynamic treatment regime which maximizes the expected 
value of the ultimate outcome of interest Y. See Laber et al. for discussion of estimating 
optimal dynamic treatment regimes.21 Suppose there is a surrogate S that is measured after 
all of the treatments have been administered, i.e., after time T, but before the ultimate 
outcome of interest Y is measured. The S-optimal dynamic treatment regime is the dynamic 
treatment regime which maximizes the expected value of the outcome S. Our goal is to find 
a good treatment regime for the ultimate outcome of interest Y. The variable S is a good 
surrogate for this goal if the expected value of Y under the S-optimal dynamic treatment 
regime is close to the expected value of Y under the Y-optimal dynamic treatment regime, 
which can be evaluated by meta-analysis in the causal-association paradigm.
Time-varying surrogates
Here we briefly discuss some issues that can arise with time-varying surrogates. Considering 
generic surrogates S1 and S2 in Figure 4, each surrogate mediates a proportion of the effect 
of treatment; e.g., A→S1→Y, A→S2→Y, or A→S1→S2→Y. In the HIV example, treatment A 
could be Zidovudine, surrogates S1 and S2 could be patient’s CD4 count at the first and 
second time points of measurement, and clinical outcome Y could be time to death. Even if 
each surrogate mediates only a small proportion of the effect of treatment, the effects of 
treatment A on S1 and S2 individually may be good predictors of the effects of A on Y due to 
the common cause of S1 and S2, the two-headed black arc in Figure 4. In this case, there 
would be a divergence between causal-effects and causal-association measures for the 
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surrogacy for the individual level of S. When considering joint surrogacy of S1 and S2, both 
of them together as a vector could be better surrogates than each one individually. In the 
causal-association paradigm, let θjv be the effect in study/group j of treatment on Sv and let 
φj be the effect in group/study j of treatment on Y. The vector {S1, ..., SV} could be a better 
predictor of φj than individual effects on single Sv.
In the causal-effects paradigm, the quality of S1 and S2 jointly versus individually can be 
assessed using “proportion mediated” measures. For instance, the ratio 
 represents the proportion mediated by both S1 and S2, 
and the ratio  represents the proportion mediated by S1 by itself 
(or marginally). Given assumptions of consistency, randomization of the treatment, and 
sequential ignorability of surrogates, these measures of proportion mediated can be 
expressed in terms of the observed data as follows:
and
As an example, consider a simple setting as in the Time-varying treatments Subsection 
where (A, S1, S2, Y) are all binary, and the treatment and surrogates are all sequentially 
ignorable. Then, for the distribution of observed data given in Table 2, the surrogates S1 and 
S2 taken together mediate a large proportion of the effect on Y but S1 alone does not. 
Specifically, one can calculate that the proportion mediated by S1 and S2 together is 
approximately 99%, while the proportion mediated by S1 alone is exactly zero. This 
illustrates that one can undervalue a surrogate by not incorporating its repeated 
measurements.
Discussion
We have discussed a conceptual framework for time-varying variables in both the causal-
effects and causal-association paradigms, focusing in particular on time-varying treatments 
and surrogates. We extended notions of surrogacy for scalar variables to corresponding 
settings with time-varying variables. Both paradigms play important roles in the surrogate 
marker problem. In general, the causal-effects paradigm is often useful for proposing causal 
surrogates that are intermediate on the causal pathway from treatments to outcome, and the 
causal-association paradigm is often useful for evaluating proxy surrogates that are not 
necessarily on the causal pathway but may be correlated with causal surrogates. Different 
approaches within the two paradigms, for example using “proportion explained” measures, 
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indirect effects, meta-analysis, or principal stratification, each have their own advantages 
and disadvantages depending on the kind of surrogate being used and on the particular study 
objectives.
VanderWeele6 discussed three types of surrogates: (1) mediator surrogates, those on the 
causal pathway from treatment to response; (2) proxy-mediator surrogates, those related to 
the intermediate variables on the causal pathway from treatment to response; and (3) 
prognostic surrogates, those not on the causal pathway and unrelated to the intermediate 
variables on the pathway. Different types of surrogates require different approaches. As 
presently developed in this paper, we have assumed time-varying surrogates in the causal-
effects paradigm are also mediator surrogates. It is also possible that the time-varying 
surrogates in the causal-association paradigm are proxy-mediator or prognostic surrogates. 
How to think about the presence of time-varying proxy-mediator or prognostic surrogates in 
the causal-effects paradigm has not been fully investigated yet.
We have considered issues arising in surrogate assessment when there are time varying 
treatments or time varying surrogates. Another type of time varying setting that would be of 
interest to consider in future research is time varying outcomes, which could be either a 
repeated measure outcome or a survival outcome.
We have focused almost exclusively on conceptual issues in this paper. A very important 
topic we have not covered in much detail is how to do statistical estimation and inference in 
time-varying settings. In the supplemental material, we provide a brief illustration of 
statistical estimation in time-varying settings. This will be critical to explore in future work, 
for which we hope this paper has provided some motivation.
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Figure 1. 
Causal diagrams of a treatment A, a surrogate S, a proxy surrogate S*, an unmeasured 
confounder U, and an outcome of interest Y
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Figure 2. 
Time-varying treatment causal diagrams of two treatments A1 and A2, a surrogate S, an 
unmeasured confounder U, and an outcome of interest Y
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Figure 3. 
Direct and indirect time-varying treatment causal diagram of two treatments A1 and A2, a 
surrogate S, an unmeasured confounder U, and an outcome of interest Y
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Figure 4. 
Time-varying surrogate causal diagram of a treatment A, two surrogates S1 and S2, an 
unmeasured confounder U, and an outcome of interest Y
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